NASDAQ$OMGAQ
Omega Therapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Omega Therapeutics reported financial results for the second quarter ended June 30, 2021.
Omega Therapeutics reported a net loss of $15.4 million for the second quarter of 2021. The company's cash and cash equivalents totaled $122.4 million as of June 30, 2021, which does not include the gross proceeds of $141.1 million from the Company’s IPO.
- Cash and cash equivalents totaled $122.4 million as of June 30, 2021, not including $141.1 million gross proceeds from IPO.
- IND submission for lead program, OTX-2002, for the treatment of Hepatocellular Carcinoma, remains on track for the first half of 2022.
- Research and development expenses for the second quarter of 2021 were $11.2 million.
- General and administrative expenses for the second quarter of 2021 were $3.6 million.
Headline financials
Revenue & EPS history
Omega Therapeutics · Revenue · Quarterly
$2.61M
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 9 quarterly earnings reports
-5.1%
Avg return
Earnings day
-8.9%
Avg return
5 days after
-12.9%
Avg return
30 days after
47%
7 / 15 earnings
Positive
+14.2%
Q1 2023
Best reaction
-47.5%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -47.5% | -25.0% | -44.8% | |
| Q3 2024 | -22.6% | -30.7% | -9.2% | |
| Q2 2024 | -0.6% | +0.0% | -11.3% | |
| Q1 2024 | -16.7% | -16.1% | -17.3% | |
| Q4 2023 | -9.9% | -15.3% | -36.6% | |
| Q3 2023 | -3.4% | +5.1% | +28.7% | |
| Q2 2023 | +2.4% | -14.2% | -23.8% | |
| Q1 2023 | +14.2% | +9.1% | +4.4% | |
| Q4 2022 | +5.6% | +7.0% | -6.7% | |
| Q3 2022 | -3.8% | — | — | |
| Q2 2022 | +9.3% | — | — | |
| Q1 2022 | +0.3% | — | — | |
| Q4 2021 | -6.4% | — | — | |
| Q3 2021 | +1.5% | — | — | |
| Q2 2021 | +0.9% | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro